Event-free survival (EFS) and overall survival (OS) of MYCN-amplified stage 2/3 neuroblastoma with or without autologous stem-cell transplantation (ASCT).

Brian H. Kushner,Shakeel Modak,Michael P. LaQuaglia,Suzanne L. Wolden,Ellen M. Basu,Stephen S. Roberts,Kim Kramer,Irene Y. Cheung,Nai-Kong V. Cheung

Event-free survival (EFS) and overall survival (OS) of MYCN-amplified stage 2/3 neuroblastoma with or without autologous stem-cell transplantation (ASCT).

2016

Brian H. Kushner
Shakeel Modak
Michael P. LaQuaglia
Suzanne L. Wolden
Ellen M. Basu
Stephen S. Roberts
Kim Kramer
Irene Y. Cheung
Nai-Kong V. Cheung

10553Background: The literature on MYCN-amplified stage 2/3 neuroblastoma is limited because this high-risk subset is uncommon. Its prognosis improved with ASCT. Reports on anti-GD2 immunotherapy d...

Keywords:

Neuroblastoma
Pathology
Autologous stem-cell transplantation
Cancer research
Medicine
Immunotherapy
event free survival
overall survival
Oncology
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations